Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ANVS
$2.88
$
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Next Earnings
2026-02-25
Beta
1.313
Average Volume
Market Cap
Last Dividend
CIK
0001477845
ISIN
US03615A1088
CUSIP
03615A108
CEO
Maria L. Maccecchini
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
8
IPO Date
2020-01-29
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease | MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of the ongoing pivotal Phase 3 AD clinical trial without modification. | GlobeNewsWire | 2026-02-12 08:00:00 |
| Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients | Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients. | GlobeNewsWire | 2025-12-18 16:35:00 |
| Annovis to Host Corporate Update Webinar on January 28, 2026 | MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. | GlobeNewsWire | 2025-12-16 08:00:00 |
| Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group | MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. | GlobeNewsWire | 2025-12-03 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| 8-K | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4/A | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-18 | 2025-11-18 | View Filing |
| 8-K | 2025-11-13 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| 424B5 | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 424B5 | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-08-20 | 2025-08-20 | View Filing |
| 8-K | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-18 | 2025-06-18 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 3 | 2025-05-16 | 2025-05-16 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| ARS | 2025-05-01 | 2025-05-01 | View Filing |
| DEFA14A | 2025-05-01 | 2025-05-01 | View Filing |
| DEF 14A | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-21 | 2025-03-21 | View Filing |
| 8-K | 2025-03-21 | 2025-03-21 | View Filing |
| SC 13G | 2025-02-10 | 2025-02-10 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-02-05 | 2025-02-04 | View Filing |
| 424B5 | 2025-02-04 | 2025-02-04 | View Filing |
| 424B5 | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2024-12-11 | 2024-12-11 | View Filing |
| 8-K | 2024-12-11 | 2024-12-11 | View Filing |
| 424B5 | 2024-12-11 | 2024-12-11 | View Filing |
| 8-K | 2024-12-09 | 2024-12-09 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-10-15 | 2024-10-15 | View Filing |
| 8-K | 2024-09-30 | 2024-09-30 | View Filing |
| 8-K | 2024-08-15 | 2024-08-15 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-07-16 | 2024-07-16 | View Filing |
| 8-K | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 8-K | 2024-07-02 | 2024-07-02 | View Filing |
| S-8 | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-13 | 2024-06-13 | View Filing |
| 8-K | 2024-06-11 | 2024-06-11 | View Filing |
| 8-K | 2024-06-05 | 2024-06-05 | View Filing |
| 8-K | 2024-05-21 | 2024-05-21 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| DEFA14A | 2024-05-06 | 2024-05-06 | View Filing |
| 8-K | 2024-05-06 | 2024-05-06 | View Filing |
| 8-K | 2024-05-02 | 2024-05-02 | View Filing |
| 8-K | 2024-05-01 | 2024-05-01 | View Filing |
| 424B5 | 2024-05-01 | 2024-05-01 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 8-K | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-04-03 | 2024-04-02 | View Filing |
| 10-K | 2024-03-29 | 2024-03-29 | View Filing |
| 8-K | 2024-03-22 | 2024-03-22 | View Filing |
| 424B5 | 2024-03-22 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-20 | 2024-03-20 | View Filing |
| 8-K | 2024-03-20 | 2024-03-19 | View Filing |
| 424B5 | 2024-03-19 | 2024-03-18 | View Filing |
| 424B5 | 2024-03-19 | 2024-03-18 | View Filing |
| 8-K | 2024-03-15 | 2024-03-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Fractal Pattern | 105.44% | 0.97 | 104 | 0.03 | 0.1 | 61.76 |
| Swarm Intelligence Strategy | 100.54% | 1 | 1202 | 0.02 | 0.06 | 56.86 |
| Neural Forcast | 99.02% | 1 | 1183 | 0.02 | 0.05 | 55.34 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |